This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
2018-08-19 seekingalpha - 1
44 of 53 S&P 500 Dividend Aristocrats stocks were deemed "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields 8/15/18.
GD APD KMB NUE SWK PX PEP JNJ CINF CVX BEN ABBV ABBV LEG MCD
July marks the ninth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $640.87.
SOJA GIS XOM SKT LTC OPRF SEP BPL MIC CINF AAPL CAH EMR SO TLP WLK O MSB CMI ETP ORI WPC SPG ADM
On the 26th of July, Cincinnati Financial reported its results for the second quarter of 2018.
Good morning. My name is Emily and I will be your conference operator today. At this time, I would like to welcome everyone to the Second Quarter 2018 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question-and-answer session. [Operator Instructions] Thank you.
Cincinnati Financial Corporation (CINF - Free Report) reported second-quarter 2018 operating income of 81 cents per share, beating the Zacks Consensus Estimate of 54 cents by a whopping 50%. Also, the bottom line improved 26.6% year over year, mainly on higher revenues, favorable underwriting performance and solid segmental results.
TRV CINF PGR RLI
Document UNITED STATES
The second-quarter earnings season is gathering momentum. Already, 87 members of the elite S&P 500 index have reported their financial numbers. Per the latest Earnings Preview, the performance of these index participants indicates 20.9% increase in total earnings on 10.3% higher revenues. The beat ratio is impressive, with 86.2% companies surpassing bottom-line expectations and 77% outperforming on the top-line front.
DB MMC AFL HIG CINF 8686 MS AFSD HGH CIT
CNH Industrial N.V. (CNHI - Free Report) is a designer and producer of agricultural and construction equipment, trucks, commercial vehicles, and buses. The Zacks Consensus Estimate for its current year earnings has been revised 1.4% downward over the last 60 days.
CARB CINF CCK MS ICBK
Cincinnati Financial Corporation (CINF - Free Report) is slated to report second-quarter 2018 results on Jul 26 after the market closes. Last reported quarter, the company delivered a negative earnings surprise of 12.20%. Let’s see, how things are shaping up for this announcement. Cincinnati Financial as a property and casualty (P&C) insurer has been exposed to unpredictable weather-related events and a considerable catastrophe loss.
PRU AFW PFK AFGE XL AFA AFGH PRU AFG PRH CINF XLGLF PJH
2018-07-23 zacks - 2
Aptose Biosciences Inc. (APTO - Free Report) is the owner and operator of a clinical-stage biotechnology company. The Zacks Consensus Estimate for its current year earnings has been revised 22.2% downward over the last 60 days.
BHI CINF BHGE APTO APS
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET